240 related articles for article (PubMed ID: 26437062)
21. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
22. Comparison of upfront tandem autologous-allogeneic transplantation versus reduced intensity allogeneic transplantation for multiple myeloma.
Sahebi F; Iacobelli S; Biezen AV; Volin L; Dreger P; Michallet M; Ljungman PT; de Witte T; Henseler A; Schaap NP; López-Corral L; Poire X; Passweg J; Hamljadi RM; Thomas SH; Schonland S; Gahrton G; Morris C; KrÖger N; Garderet L
Bone Marrow Transplant; 2015 Jun; 50(6):802-7. PubMed ID: 25798673
[TBL] [Abstract][Full Text] [Related]
23. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 2 Carmustine-Containing Regimens in the Rituximab Era: Excellent Outcomes Even in Poor-Risk Patients.
Caimi PF; William BM; Silva Rondon CH; Fu P; Cooper BW; Campagnaro EL; Gerson SL; Reese-Koc J; Fox R; Creger RJ; de Lima M; Lazarus HM
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1926-31. PubMed ID: 26087475
[TBL] [Abstract][Full Text] [Related]
25. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT.
Sureda A; Genadieva Stavrik S; Boumendil A; Finel H; Khvedelidze I; Dietricht S; Dreger P; Hermine O; Kyriakou C; Robinson S; Schmitz N; Schouten HC; Tanase A; Montoto S
Bone Marrow Transplant; 2020 Nov; 55(11):2170-2179. PubMed ID: 32415225
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?
Klyuchnikov E; Bacher U; Kroll T; Shea TC; Lazarus HM; Bredeson C; Fenske TS
Bone Marrow Transplant; 2014 Jan; 49(1):1-7. PubMed ID: 23708703
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis.
Wang J; Duan X; Yang L; Liu X; Hao C; Dong H; Gu H; Tang H; Dong B; Zhang T; Gao G; Liang R
Cell Transplant; 2020; 29():963689720975397. PubMed ID: 33238731
[TBL] [Abstract][Full Text] [Related]
28. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma.
Moustafa MA; Ramdial JL; Tsalatsanis A; Khimani F; Dholaria B; Bojanini L; Brooks T; Zain J; Bennani NN; Braunstein Z; Brammer JE; Beitinjaneh A; Jagadeesh D; Weng WK; Kumar A; Kharfan-Dabaja MA; Ahmed S; Murthy HS
Transplant Cell Ther; 2024 May; 30(5):516.e1-516.e10. PubMed ID: 38431075
[TBL] [Abstract][Full Text] [Related]
29. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Phipps C; Gopal AK; Storer BE; Cassaday RD; Press OW; Till BG; Pagel JM; Palanca-Wessels MC; Philip M; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Chauncey T; Maloney DG; Libby EN
Leuk Lymphoma; 2015 Jan; 56(1):92-6. PubMed ID: 24707941
[TBL] [Abstract][Full Text] [Related]
30. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All?
Hamadani M; Horowitz MM
J Oncol Pract; 2017 Dec; 13(12):798-806. PubMed ID: 29232542
[TBL] [Abstract][Full Text] [Related]
32. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.
Avivi I; Canals C; Vernant JP; Wulf G; Nagler A; Hermine O; Petersen E; Yakoub-Agha I; Craddock C; Schattenberg A; Niederwieser D; Thomson K; Blaise D; Attal M; Pfreundschuh M; Passweg J; Russell N; Dreger P; Sureda A;
Bone Marrow Transplant; 2014 May; 49(5):671-8. PubMed ID: 24510071
[TBL] [Abstract][Full Text] [Related]
33. Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation.
Pemmaraju N; Tanaka MF; Ravandi F; Lin H; Baladandayuthapani V; Rondon G; Giralt SA; Chen J; Pierce S; Cortes J; Kantarjian H; Champlin RE; De Lima M; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):485-92. PubMed ID: 23769669
[TBL] [Abstract][Full Text] [Related]
34. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis.
Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
36. Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
Fakhri B; Yilmaz E; Gao F; Ambinder RF; Jones R; Bartlett NL; Cashen A; Wagner-Johnston N
Leuk Lymphoma; 2021 Oct; 62(10):2408-2415. PubMed ID: 33988071
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma.
Furqan F; Ahn KW; Chen Y; Kaur M; Abutalib SA; Ahmed N; Ahmed S; Kharfan-Dabaja MA; Friedberg J; Gregory T; Hill L; Sterling C; Barta SK; Shadman M; Perales MA; Zain J; Herrera AF; Sauter C; Hamadani M
Br J Haematol; 2023 Jan; 200(1):54-63. PubMed ID: 36120837
[TBL] [Abstract][Full Text] [Related]
38. Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma.
Ingram W; Devereux S; Das-Gupta EP; Russell NH; Haynes AP; Byrne JL; Shaw BE; McMillan A; Gonzalez J; Ho A; Mufti GJ; Pagliuca A
Br J Haematol; 2008 Apr; 141(2):235-43. PubMed ID: 18318762
[TBL] [Abstract][Full Text] [Related]
39. (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.
Abou-Nassar KE; Stevenson KE; Antin JH; McDermott K; Ho VT; Cutler CS; LaCasce AS; Jacobsen ED; Fisher DC; Soiffer RJ; Alyea EP; Koreth J; Freedman AS
Bone Marrow Transplant; 2011 Dec; 46(12):1503-9. PubMed ID: 21258420
[TBL] [Abstract][Full Text] [Related]
40. Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.
Epperla N; Badar T; Szabo A; Vaughn J; Borson S; Saini NY; Patel RD; Shah NN; Hamadani M; Ahmed S; Cashen AF; Fenske TS
Blood Adv; 2019 Jun; 3(11):1661-1669. PubMed ID: 31167818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
